Jun 2026 (Q2 FY26) — Aug 12, 2026
Annexon Q2 FY26 — ARCHER II Program Expanded, GBS BLA on Track
Read the full callAnnexon (ANNX) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Annexon earnings: last reported Wed, 12 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | Quarterly, as filed | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Operating margin | Operating profit / revenue | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Net profit | -55.3 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$4.01 +17.60% · +$0.6
Performance +27.3% 1Y
1Y: $3.15 on 17 Oct 2025 → $4.01. High $6.96 (22 Jan 2026), low $2.68 (13 Nov 2025).
- Previous close
- $3.41
- 52-week range
- $2.68 – $6.96
- One year
- +26.90%
Overview
- Symbol
- ANNX
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Annexon earnings calls (ANNX)
Financials
What the filings say
Net profit, year on year: −13% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating profit | -39 | -52 | -57 | -52 | -57 | -50 | -46 | -57 |
| Net profit | -35 | -49 | -54 | -49 | -55 | -48 | -44 | -55 |
| EPS ($ per share) | -0.25 | — | -0.37 | -0.34 | -0.37 | — | -0.23 | -0.28 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -103 | -166 | -296 | -438 | -572 | -711 | -917 |
| Total liabilities | 6 | 12 | 55 | 54 | 47 | 57 | 66 |
| Fixed assets | 2 | 2 | 18 | 17 | 15 | 13 | 11 |
| Total assets | 50 | 356 | 287 | 285 | 298 | 350 | 278 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -28 | -53 | -106 | -116 | -121 | -118 | -186 |
| Cash from investing | -0 | -83 | -88 | 58 | 71 | -219 | 190 |
| Cash from financing | 28 | 361 | 2 | 123 | 136 | 161 | 109 |
| Net cash flow | -0 | 225 | — | — | — | — | — |
| Capital expenditure | -0 | -0 | -2 | -7 | -0 | -0 | -0 |
| Free cash flow | -29 | -54 | -108 | -123 | -121 | -118 | -186 |
Insider filings
30 filings between Oct 30, 2025 and Sep 24, 2026.
Open market
decisions to buy or sellPurchases
$12.41M
14 purchases by 4 insiders
Sales
$313.4K
10 sales by 5 insiders
Compensation
not trading decisions- 5
- Award — granted as compensation
- 1
- Option exercise — converted options into shares
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Satter Muneer A | $11.97M | — | May 28, 2026 |
| Carson William H. | $193.3K | — | May 11, 2026 |
| Choi Jung | $138.3K | — | Dec 1, 2025 |
| Love Douglas | $99.8K | — | Sep 24, 2026 |
| Yednock Ted | — | $70.3K | Mar 2, 2026 |
| Lew Jennifer | — | $70.3K | Mar 2, 2026 |
| ARTIS DEAN RICHARD | — | $59.0K | Mar 2, 2026 |
| Dananberg Jamie | — | $58.6K | Mar 2, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 24, 2026 | Love Douglas PRESIDENT AND CEO | Purchase | 26,065 | $99.8K |
| Jun 11, 2026 | Yednock Ted EVP & CHIEF INNOVATION OFFICER | Option exercise 10b5-1 plan | 30,646 | $56.7K |
| May 28, 2026 | Satter Muneer A Director | Purchase | 613,497 | $3.32M |
| May 11, 2026 | Carson William H. Director | Purchase 10b5-1 plan | 8,000 | $46.2K |
| Apr 10, 2026 | Carson William H. Director | Purchase 10b5-1 plan | 8,000 | $49.6K |
| Mar 10, 2026 | Carson William H. Director | Purchase 10b5-1 plan | 8,000 | $45.4K |
| Mar 2, 2026 | Dananberg Jamie CHIEF MEDICAL OFFICER | Sale | 5,820 | $31.6K |
| Mar 2, 2026 | Overdorf Michael EVP & CHIEF BUSINESS OFFICER | Sale | 4,339 | $23.5K |
| Mar 2, 2026 | Yednock Ted EVP & CHIEF INNOVATION OFFICER | Sale | 5,566 | $30.2K |
| Mar 2, 2026 | ARTIS DEAN RICHARD EVP & CHIEF SCIENTIFIC OFFICER | Sale | 5,894 | $32.0K |
| Mar 2, 2026 | Lew Jennifer EVP & CHIEF FINANCIAL OFFICER | Sale | 5,565 | $30.2K |
| Feb 19, 2026 | Dananberg Jamie CHIEF MEDICAL OFFICER | Award | 56,250 | $0 |
| Feb 19, 2026 | Overdorf Michael EVP & CHIEF BUSINESS OFFICER | Award | 62,500 | $0 |
| Feb 19, 2026 | Yednock Ted EVP & CHIEF INNOVATION OFFICER | Award | 62,500 | $0 |
| Feb 19, 2026 | ARTIS DEAN RICHARD EVP & CHIEF SCIENTIFIC OFFICER | Award | 62,500 | $0 |
| Feb 19, 2026 | Lew Jennifer EVP & CHIEF FINANCIAL OFFICER | Award | 62,500 | $0 |
| Feb 18, 2026 | Dananberg Jamie CHIEF MEDICAL OFFICER | Sale | 5,290 | $27.0K |
| Feb 18, 2026 | Overdorf Michael EVP & CHIEF BUSINESS OFFICER | Sale | 6,225 | $31.7K |
| Feb 18, 2026 | Yednock Ted EVP & CHIEF INNOVATION OFFICER | Sale | 7,857 | $40.1K |
| Feb 18, 2026 | ARTIS DEAN RICHARD EVP & CHIEF SCIENTIFIC OFFICER | Sale | 5,290 | $27.0K |
| Feb 18, 2026 | Lew Jennifer EVP & CHIEF FINANCIAL OFFICER | Sale | 7,851 | $40.1K |
| Dec 30, 2025 | Carson William H. Director | Purchase 10b5-1 plan | 4,115 | $20.7K |
| Dec 1, 2025 | Carson William H. Director | Purchase 10b5-1 plan | 4,115 | $18.4K |
| Dec 1, 2025 | Choi Jung Director | Purchase | 33,000 | $138.3K |
| Nov 21, 2025 | Satter Muneer A Director | Purchase | 422,613 | $1.81M |
| Nov 20, 2025 | Satter Muneer A Director | Purchase | 400,000 | $1.79M |
| Nov 19, 2025 | Satter Muneer A Director | Purchase | 500,000 | $1.97M |
| Nov 18, 2025 | Satter Muneer A Director | Purchase | 500,000 | $1.59M |
| Nov 17, 2025 | Satter Muneer A Director | Purchase | 500,000 | $1.50M |
| Oct 30, 2025 | Carson William H. Director | Purchase 10b5-1 plan | 4,115 | $13.0K |
| Sep 30, 2025 | Carson William H. Director | Purchase 10b5-1 plan | 4,115 | $12.6K |
| Sep 2, 2025 | Carson William H. Director | Purchase 10b5-1 plan | 4,115 | $8.6K |
| Jul 30, 2025 | Carson William H. Director | Purchase 10b5-1 plan | 4,115 | $10.0K |
| Jul 14, 2025 | Lew Jennifer EVP & CHIEF FINANCIAL OFFICER | Sale | 1,117 | $2.9K |
| Jul 14, 2025 | Yednock Ted EVP & CHIEF INNOVATION OFFICER | Sale | 1,116 | $2.9K |
| Jul 14, 2025 | Overdorf Michael EVP & CHIEF BUSINESS OFFICER | Sale | 853 | $2.2K |
| Jun 30, 2025 | Carson William H. Director | Purchase 10b5-1 plan | 4,115 | $10.1K |
| Feb 18, 2025 | Overdorf Michael EVP & CHIEF BUSINESS OFFICER | Sale | 6,618 | $19.5K |
| Feb 18, 2025 | Dananberg Jamie CHIEF MEDICAL OFFICER | Sale | 5,521 | $16.3K |
| Feb 18, 2025 | ARTIS DEAN RICHARD EVP & CHIEF SCIENTIFIC OFFICER | Sale | 5,515 | $16.4K |
| Feb 18, 2025 | Yednock Ted EVP & CHIEF INNOVATION OFFICER | Sale | 8,345 | $24.3K |
| Feb 18, 2025 | Lew Jennifer EVP & CHIEF FINANCIAL OFFICER | Sale | 6,912 | $20.2K |
| Feb 13, 2025 | Love Douglas PRESIDENT AND CEO | Sale | 5,021 | $14.8K |
| Feb 13, 2025 | Overdorf Michael EVP & CHIEF BUSINESS OFFICER | Sale | 1,425 | $4.3K |
| Feb 13, 2025 | Yednock Ted EVP & CHIEF INNOVATION OFFICER | Sale | 1,783 | $5.3K |
| Feb 13, 2025 | Lew Jennifer EVP & CHIEF FINANCIAL OFFICER | Sale | 1,786 | $5.3K |
| Jan 6, 2025 | Love Douglas PRESIDENT AND CEO | Option exercise | 37,994 | $53.6K |
| Dec 2, 2024 | Carson William H. Director | Purchase 10b5-1 plan | 3,200 | $17.1K |
| Oct 30, 2024 | Love Douglas PRESIDENT AND CEO | Option exercise | 36,050 | $66.7K |
| Oct 30, 2024 | Love Douglas PRESIDENT AND CEO | Option exercise | 78,399 | $145.0K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Annexon, Inc.
Free account. Everything above stays public.
Write why you follow Annexon, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading